Kairos Pharma to Present Cutting-Edge Cancer Treatment Research at Investor Conference

Kairos Pharma Ltd., a biotechnology company specializing in oncology therapeutics, will present its groundbreaking cancer research at the D. Boral Capital Inaugural Global Conference in New York City. CEO and Chairman John Yu will engage in one-on-one investor meetings, highlighting the company's innovative approach to addressing drug resistance in cancer treatment.

The company's lead candidate, ENV105, represents a significant advancement in cancer research by targeting CD105, a protein identified as a critical driver of treatment resistance. By focusing on this specific protein, ENV105 aims to restore the effectiveness of standard cancer therapies across multiple cancer types, potentially transforming treatment outcomes for patients.

Currently, ENV105 is undergoing clinical trials in two critical areas: a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials represent important steps in addressing significant unmet medical needs in oncology, where drug resistance remains a substantial challenge for patients and healthcare providers.

The research strategy employed by Kairos Pharma utilizes structural biology to understand and counteract the mechanisms of drug resistance and immune suppression in cancer. By targeting CD105, which elevates in response to standard therapies and contributes to disease relapse, ENV105 offers a promising approach to improving cancer treatment efficacy.

The upcoming conference provides an opportunity for Kairos Pharma to showcase its innovative research to potential investors and highlight the potential impact of its therapeutic approach. The company's focus on developing targeted therapies that can overcome treatment resistance represents a critical area of oncological research with potentially transformative implications for cancer care.